• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国新冠病毒灭活疫苗研发综述:聚焦特殊人群的安全性与有效性

A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.

作者信息

Hu Lidan, Sun Jingmiao, Wang Yan, Tan Danny, Cao Zhongkai, Gao Langping, Guan Yuelin, Jia Xiuwei, Mao Jianhua

机构信息

Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310030, China.

出版信息

Vaccines (Basel). 2023 May 31;11(6):1045. doi: 10.3390/vaccines11061045.

DOI:10.3390/vaccines11061045
PMID:37376434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10302808/
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been widespread globally, and vaccination is critical for preventing further spread or resurgence of the outbreak. Inactivated vaccines made from whole inactivated SARS-CoV-2 virus particles generated in Vero cells are currently the most widely used COVID-19 vaccines, with China being the largest producer of inactivated vaccines. As a result, the focus of this review is on inactivated vaccines, with a multidimensional analysis of the development process, platforms, safety, and efficacy in special populations. Overall, inactivated vaccines are a safe option, and we hope that the review will serve as a foundation for further development of COVID-19 vaccines, thus strengthening the defense against the pandemic caused by SARS-CoV-2.

摘要

2019冠状病毒病(COVID-19)大流行由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,已在全球广泛传播,接种疫苗对于预防疫情的进一步传播或复发至关重要。由在Vero细胞中产生的全灭活SARS-CoV-2病毒颗粒制成的灭活疫苗是目前使用最广泛的COVID-19疫苗,中国是灭活疫苗的最大生产国。因此,本综述的重点是灭活疫苗,对其研发过程、平台、安全性以及在特殊人群中的疗效进行多维度分析。总体而言,灭活疫苗是一种安全的选择,我们希望本综述能为COVID-19疫苗的进一步研发奠定基础,从而加强对SARS-CoV-2所致大流行的防御。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8201/10302808/0c11551f4ce1/vaccines-11-01045-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8201/10302808/0c11551f4ce1/vaccines-11-01045-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8201/10302808/0c11551f4ce1/vaccines-11-01045-g001.jpg

相似文献

1
A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.中国新冠病毒灭活疫苗研发综述:聚焦特殊人群的安全性与有效性
Vaccines (Basel). 2023 May 31;11(6):1045. doi: 10.3390/vaccines11061045.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗:除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
4
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
5
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.两种灭活严重急性呼吸综合征冠状病毒2疫苗加强接种对成人有症状的冠状病毒病感染的疗效和安全性:在阿布扎比进行的一项双盲、随机、安慰剂对照3期试验的结果
Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299.
6
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.一项在 18-59 岁健康成年人中评估 SARS-CoV-2 灭活疫苗的有效性、安全性和免疫原性的 III 期、观察者盲法、随机、安慰剂对照研究:印度尼西亚的中期分析。
Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24.
7
Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.冠状病毒疫苗对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)及其变体的有效性。
Iran J Allergy Asthma Immunol. 2021 Dec 8;20(6):647-671. doi: 10.18502/ijaai.v20i6.8016.
8
Myocarditis Following Inactivated SARS-CoV-2 Vaccine (Vero Cell) in an Adult Female in Vietnam: A Case Report.越南一名成年女性接种灭活新型冠状病毒2疫苗(Vero细胞)后发生心肌炎:病例报告
Int Med Case Rep J. 2023 Sep 15;16:551-559. doi: 10.2147/IMCRJ.S410806. eCollection 2023.
9
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒(灭活)疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV:一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
10
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.腺病毒 5 型载体疫苗和灭活 COVID-19 疫苗对由 B.1.617.2(德尔塔)变异株引起的有症状 COVID-19、COVID-19 肺炎和重症 COVID-19 的有效性:来自中国云南 2021 年暴发疫情的证据。
Vaccine. 2022 May 3;40(20):2869-2874. doi: 10.1016/j.vaccine.2022.03.067. Epub 2022 Apr 1.

引用本文的文献

1
Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies.利用细胞免疫研发抗呼吸道病毒的下一代疫苗:作用机制、平台及优化策略
Front Immunol. 2025 Aug 13;16:1618406. doi: 10.3389/fimmu.2025.1618406. eCollection 2025.
2
Neutralizing antibody response to Omicron subvariants BA.1 and BA.5 in children and adolescents following the two-dose CoronaVac protocol (Immunita-002, Brazil): a 12-month longitudinal study.两剂科兴疫苗接种方案(巴西Immunita-002)后儿童和青少年对奥密克戎亚型BA.1和BA.5的中和抗体反应:一项为期12个月的纵向研究
Front Immunol. 2025 Jul 15;16:1589733. doi: 10.3389/fimmu.2025.1589733. eCollection 2025.
3

本文引用的文献

1
Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study.灭活新冠疫苗对广州奥密克戎BA.2感染的保护作用:一项检测阴性病例对照的真实世界研究
Vaccines (Basel). 2023 Mar 1;11(3):566. doi: 10.3390/vaccines11030566.
2
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.延长 COVID-19 疫苗接种间隔时间可提高 HIV 感染者的血清转化率。
Front Immunol. 2023 Mar 2;14:1152695. doi: 10.3389/fimmu.2023.1152695. eCollection 2023.
3
Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy.
Epidemiological intricacies of respiratory pathogens: a single-center study on infection dynamics in Beijing, 2023-2024.
呼吸道病原体的流行病学复杂性:2023 - 2024年北京感染动态的单中心研究
Front Public Health. 2025 Jun 26;13:1581815. doi: 10.3389/fpubh.2025.1581815. eCollection 2025.
4
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.SARS-CoV-2蛋白亚单位重组疫苗(Indovac®)在印度尼西亚18岁及以上健康人群中的安全性和免疫原性:一项I期、观察者盲法、随机、对照研究。
Hum Vaccin Immunother. 2025 Dec;21(1):2501467. doi: 10.1080/21645515.2025.2501467. Epub 2025 May 17.
5
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代:SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
6
Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.基于水疱性口炎病毒(VSV)的复制缺陷型疫苗可引发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和流感病毒的保护性反应。
Sci Adv. 2025 Jan 31;11(5):eadq4545. doi: 10.1126/sciadv.adq4545. Epub 2025 Jan 29.
7
Seroconversion and dynamics of IgG anti-SARS-CoV-2 antibodies during the pandemic: A two-month observation cohort study on the population of Sleman in Indonesia.疫情期间抗SARS-CoV-2 IgG抗体的血清转化及动态变化:印度尼西亚斯莱曼人群的一项为期两个月的观察队列研究。
PLoS One. 2025 Jan 2;20(1):e0316360. doi: 10.1371/journal.pone.0316360. eCollection 2025.
8
Vaccines for Respiratory Viruses-COVID and Beyond.呼吸道病毒疫苗——新冠及其他。
Vaccines (Basel). 2024 Aug 22;12(8):936. doi: 10.3390/vaccines12080936.
9
Alterations of plasma metabolomes and their correlations with immunogenicity in maintenance hemodialysis patients receiving different COVID-19 vaccine regimens.不同 COVID-19 疫苗方案的维持性血液透析患者的血浆代谢组学改变及其与免疫原性的相关性。
Physiol Rep. 2024 Aug;12(16):e70005. doi: 10.14814/phy2.70005.
10
Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.SpikoGen®,一种 Advax-CpG55.2 佐剂的重组刺突蛋白疫苗的临床开发。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2363016. doi: 10.1080/21645515.2024.2363016. Epub 2024 Jun 5.
妊娠期首三月接种灭活 COVID-19 疫苗的安全性和有效性。
Int J Infect Dis. 2023 May;130:196-202. doi: 10.1016/j.ijid.2023.03.017. Epub 2023 Mar 15.
4
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.三剂科兴疫苗后,雾化腺病毒载体5型新冠疫苗、肌肉注射腺病毒载体5型新冠疫苗或灭活新冠疫苗科兴疫苗作为第二剂加强针的安全性和免疫原性:一项多中心、开放标签、4期随机试验。
Lancet Respir Med. 2023 Jul;11(7):613-623. doi: 10.1016/S2213-2600(23)00049-8. Epub 2023 Mar 7.
5
Hesitancy to Receive the Second COVID-19 Vaccine Booster Dose among Older Adults in Hong Kong: A Random Telephone Survey.香港老年人对新冠病毒病第二剂加强针接种的犹豫态度:一项随机电话调查
Vaccines (Basel). 2023 Feb 8;11(2):392. doi: 10.3390/vaccines11020392.
6
The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients.灭活 COVID-19 疫苗在老年肺结核患者中的安全性和免疫原性。
Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):503-512. doi: 10.1007/s10096-023-04566-0. Epub 2023 Feb 28.
7
Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines.2 型糖尿病患者接种新冠病毒灭活疫苗后,抗体反应受损。
Virol J. 2023 Feb 7;20(1):22. doi: 10.1186/s12985-023-01983-7.
8
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.中和抗体对 SARS-CoV-2 感染的保护作用和保护机制及其潜在的临床意义。
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
9
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
10
Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis.老年人接种新冠疫苗的有效性和安全性:一项系统评价与荟萃分析
Vaccines (Basel). 2022 Dec 23;11(1):33. doi: 10.3390/vaccines11010033.